- Home
- PCRX vs EOS Comparison
PCRX vs EOS Comparison
Compare PCRX & EOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- EOS
- Stock Information
- Founded
- PCRX 2006
- EOS 2005
- Country
- PCRX United States
- EOS United States
- Employees
- PCRX N/A
- EOS N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- EOS Trusts Except Educational Religious and Charitable
- Sector
- PCRX Health Care
- EOS Finance
- Exchange
- PCRX Nasdaq
- EOS Nasdaq
- Market Cap
- PCRX 1.2B
- EOS 1.3B
- IPO Year
- PCRX 2011
- EOS N/A
- Fundamental
- Price
- PCRX $22.76
- EOS $23.44
- Analyst Decision
- PCRX Buy
- EOS
- Analyst Count
- PCRX 5
- EOS 0
- Target Price
- PCRX $32.40
- EOS N/A
- AVG Volume (30 Days)
- PCRX 479.4K
- EOS 84.1K
- Earning Date
- PCRX 11-05-2025
- EOS 01-01-0001
- Dividend Yield
- PCRX N/A
- EOS 6.80%
- EPS Growth
- PCRX N/A
- EOS N/A
- EPS
- PCRX N/A
- EOS N/A
- Revenue
- PCRX $705,848,000.00
- EOS N/A
- Revenue This Year
- PCRX $7.36
- EOS N/A
- Revenue Next Year
- PCRX $10.07
- EOS N/A
- P/E Ratio
- PCRX N/A
- EOS N/A
- Revenue Growth
- PCRX 2.25
- EOS N/A
- 52 Week Low
- PCRX $16.00
- EOS $15.62
- 52 Week High
- PCRX $27.64
- EOS $20.63
- Technical
- Relative Strength Index (RSI)
- PCRX 35.28
- EOS 38.74
- Support Level
- PCRX $24.31
- EOS $23.64
- Resistance Level
- PCRX $26.05
- EOS $24.35
- Average True Range (ATR)
- PCRX 0.82
- EOS 0.34
- MACD
- PCRX -0.20
- EOS -0.05
- Stochastic Oscillator
- PCRX 18.36
- EOS 9.00
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About EOS Eaton Vance Enhance Equity Income Fund II
Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in common stocks. It invests in a portfolio of large and mid-cap securities in sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.